Overview

Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the pharmacokinetics (PK) of roflumilast and its metabolite roflumilast N-oxide after single and repeated oral administrations of roflumilast 500 μg in healthy Chinese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca